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ABSTRACT 
Introduction: The frequent recolonization of treated sites by 
periodontopathogens and the emergence of antibiotic resistance have led to a call for 
new therapeutic approaches for managing periodontal diseases. As probiotics are 
considered a new tool for combating infectious diseases,   we systematically reviewed 
the evidences for their effectiveness in the management of periodontitis. Areas 
covered: An electronic search was performed in the MEDLINE, SCOPUS and 
Cochrane Library databases up to March 2016 using the terms ‘periodontitis’, ‘chronic 
periodontitis’, ‘probiotic(s)’, ‘prebiotic(s)’, ‘symbiotic(s)’, ‘Bifidobacterium and 
‘Lactobacillus’. Only randomized controlled trials (RCT) were included in the present 
study. Analysis of 12 RCT revealed that in general, oral administration of probiotics 
improved the recognized clinical signs of chronic and aggressive periodontitis such as 
probing pocket depth, bleeding on probing, and attachment loss, with a concomitant 
reduction in the levels of major periodontal pathogens. Continuous probiotic 
administration, laced mainly with Lactobacillus species, was necessary to maintain 
these benefits. Expert commentary: Oral administration of probiotics is a safe and 
effective adjunct to conventional mechanical treatment (scaling) in the management of 
periodontitis, specially the chronic disease entity. Their adjunctive use  is likely to 
improve disease indices and reduce the need for antibiotics. 
 
 
Key words: periodontal diseases, periodontitis, probiotics, Lactobacillus, 
Streptococcus, inflammation, dental hygiene.  
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1. INTRODUCTION  
Periodontal disease is perhaps the commonest human affliction. Inflammation of 
the periodontium, periodontitis, is a chronic inflammatory disease with a complex 
aetiology, caused mainly by Gram-negative bacteria that destroys supporting structures 
of the tooth viz, the gingivae, periodontal ligament and alveolar bone [1]. Severe 
periodontitis can result in tooth mobility caused by bone resorption, and may lead to 
loss of the affected tooth [2]. 
Periodontal pathogens, besides causing tooth loss, may have systemic impact 
through a variety of mechanisms. These include bacteremia caused by the translocation 
of periodontal pathogens into the systemic circulation, and endotoxaemias due to the 
lipopolysaccharides of the periodontopathogenic bacteria. Additionally the production 
of interleukins generated through the chronic inflammatory process has been linked to 
atherosclerotic vascular disease [3], adverse pregnancy outcomes, diabetes and 
nosocomial pneumonias [4]. Porphyromonas gingivalis, Treponema denticola, 
Tannerella forsythia and Aggregatibacter actinomycetemcomitans have all been 
implicated as the major bacterial agents of periodontitis [5]. However, recent 
metagenomic studies suggest that a yet to be identified, diverse range of periodontitis-
associated microbiota may be involved in the disease process [6]. 
The conventional treatment of periodontitis entails non-surgical management 
aimed at controlling the pathogenic plaque biofilm and calculus burden from the 
coronal and root surfaces by mechanical procedures (scaling), together with improved 
personal hygiene, thus reducing inflammation and pocket depths, and promoting 
periodontal reattachment [2,7]. In severe cases antibiotic therapy may be required to 
facilitate disease resolution [8].  
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Such therapeutic approaches are not always associated with success and the 
frequent recolonization of treated sites by periodontopathogens, as well the emergence 
of antibiotic resistance, have led to a call for new therapeutic approaches for managing 
periodontal diseases [9]. One such approach that has recently gained  universal 
popularity is probiotic therapy. Probiotics seem to be an alternative biological approach 
to modify, at least in the short term, the periodontal plaque biofilm and help control 
periodontitis [10]. 
Probiotics are defined as ‘live microorganisms that, when administered in 
adequate amounts, confer a health benefit on the host’ [11]. The most common 
probiotics belong to two main genera Lactobacillus and Bifidobacterium [12]. L. 
acidophillus and L. rhamnosus have been associated with antibacterial as well as 
antifungal effects [13,14], while L. reuteri and L. salivarius are known to suppress both 
cariogenic [15] and periodontal pathogens [16-18].  
In dentistry, probiotics have been employed as useful adjuncts for the reduction 
of caries development [19], suppressing oral Candida infections [20], and controlling 
halitosis [21]. Recent publications have also demonstrated the potential benefit of 
probiotic administration for managing periodontal diseases, especially periodontitis 
[16,22]. For instance, in one study,  probiotic supplements together with conventional 
mechanical treatment led to clinical improvement of periodontitis [17], similar to   
improvements due to antibiotic administration,   [23]. These and related new findings 
have led to a totally new paradigm for managing periodontal infections. 
Therefore, the aim of this systematic review was to explore the available clinical 
evidence on the efficacy of probiotic therapy in managing chronic periodontitis. PICOS 
criteria were adopted in this systematic review (Table 1).  
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2. MATERIAL AND METHODS 
2.1 Protocol and registration 
The systematic review was registered in the International Prospective Register of 
Systematic Reviews ‘PROSPERO’; Registration number is: CRD42015020560 [24]. 
2.2 Eligibility criteria and search strategy  
A critical review of the literature was conducted to select pertinent articles 
published in the literature. An advanced mode electronic search was performed in the 
MEDLINE (PubMed), SCOPUS and Cochrane Library databases up to March 2016. 
The search covered all human clinical trials conducted from the year 2000 onwards, 
wherein   the effect of probiotic bacteria on periodontitis was evaluated. The literature 
search strategy in the PubMed database was performed using the following terms: 
‘chronic periodontitis OR periodontitis’ AND ‘probiotic OR probiotics OR prebiotic 
OR prebiotics OR symbiotic OR symbiotics OR Bifidobacterium OR Lactobacillus’. 
The search terms applied to Cochrane Library were ‘probiotic’ and ‘periodontitis’. The 
search strategy in the Scopus database used the search terms “probiotic” and 
‘periodontitis’, excluding Reviews, Book Chapters and Books. In addition, 
bibliographies of the selected articles were manually searched. 
2.3 Selection criteria  
The inclusion criteria were:  
- Studies testing probiotic bacteria in the management of periodontitis; 
- Humans studies; 
- Randomized controlled clinical trials (RCTs). 
The exclusion criteria were:  
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- Absence of information regarding the methodology of the clinical study; 
- Reviews and studies on animals;  
- Studies devoid of data on clinical parameters of periodontitis and/or associated 
periodontal pathogens. 
2.4 Article review and data extraction 
The study selection process was according to PRISMA guidelines [25], as 
illustrated in Figure 1. Two examiners (V.H.M. and K.H.I) screened the titles and 
abstracts obtained through the described search strategy. The screening was performed 
according to the following criteria: randomized clinical trials and clinical and/or 
microbiological outcome. Full reports were obtained for all the studies that were 
considered eligible for inclusion in the review. Discrepancies and doubts were resolved 
in the first instance through data check and discussion. When there was no consensus, 
a third examiner was consulted. In the absence of pertinent data, the authors of the 
identified articles were contacted to provide further details. Kappa values for measuring 
agreement between two authors were equal to 0.89 (p<0.001), thus reflecting an almost 
perfect inter-author agreement. 
Data extracted from the randomized clinical trials (RCTs) included the year of 
publication, the names of authors, the study design, the population demographics, the 
probiotic bacterial strains used and their mode of administration such as the frequency 
and duration, and the follow-up procedures, other associated treatment modes, the 
adverse effects, if any, the key parameters studied, and finally, the outcome measures.  
2.5 Risk of bias assessment  
A quality assessment of the studies included in the present review was performed 
as per the recommendations of the Cochrane Collaboration for systematic reviews of 
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interventions [26]. The quality assessment focused on the following criteria: random 
sequence generation and allocation concealment (selection bias), blinding of 
participants and personnel (performance bias), blinding of outcome assessment 
(detection bias), incomplete outcome data (attrition bias) and selective reporting 
(reporting bias). 
The risk of bias of each study was categorized according to the following criteria: 




3.1 Study selection  
 The systematic search yielded 214 studies pertinent to the current review. After 
excluding duplicate references, a total of 192 articles/studies were screened, and each 
of the titles and abstracts were scrutinized for selection fitness. A total of 157 studies 
were excluded during the latter screening phase leading to 35 residual studies that were 
deemed fit for further analysis. 
 These 35 studies were further filtered and 23 excluded (Figure 1). A total of 12 
studies were included and analyzed in the final review (Table 3). 
3.2 Study characteristics 
 All randomized clinical trials selected were double-blinded studies, except for the 
study of Shah et al. [23]. The study of Della Ricca et al. [27] was classified as double-
blinded by the authors, however its veracity appeared questionable as no placebo group 
was used. A total of ten studies were placebo-controlled [16-18,22,28-33], whilst the 
remainder were paired-comparison studies [23,27]. Both parallel [16,17,22,28-30,33] 
and split-mouth designs [29] were identified within the RCTs. 
 Four different Lactobacillus species, i.e. Lactobacillus reuteri in five studies 
[16,17,22,28,29], Lactobacillus salivarius in three studies [18,30,31], Lactobacillus 
brevis in two studies [23,27] and Lactobacillus rhamnosus in a single study [33] were 
evaluated for their probiotic effect against periodontitis. A single study also evaluated 
the effect of a probiotic product with three different streptococci belonging to 
Streptococcus oralis, S. uberis, and S. rattus species [32]. The organisms were orally 
administered either as lozenges, tablets, sachet or as suspensions in soybean oil from 
four days to 12 weeks. In nine of twelve studies, the probiotic was self administered 
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orally and the probiotic concentrations varied between 2.0x107, 2.0x108, 4.0x108 and 
2.1x109 colony forming units (CFUs) per day. 
 In terms of the mode of administration, the patients were asked to keep the 
probiotic tablets in the mouth and dissolve without chewing [32], whilst in the case of 
the lozenges the patients were asked to suck the lozenges after they brushed their teeth 
[22]. When the probiotic-containing sachet was used, the patients were instructed to 
dissolve the content of one sachet in water and ingest it after brushing their teeth [33]. 
In one study evaluating the efficacy of probiotic suspended in soybean oil, patients were 
instructed to place the product in their mouths and spread it over the surface of the oral 
mucosa and teeth using tongue movements [18]. 
3.3 Risk of bias within studies 
 The Cochrane Collaboration’s tool for assessing the risk of bias in randomized 
trials was used to identify papers with intrinsic flaws in methodology and design [34], 
thus ascertaining the quality of each study. As shown in Table 2, all studies had a 
random sequence generation, using computer-based randomization programs, block 
approach or tables. However, the allocation concealment was not totally clear in four 
studies [18,23,27,30]. The studies of Della Riccia et al. [27] and Shah et al. [23] also 
had an unclear risk of bias in blinding of patients, as well as the researchers, and 
outcome assessment. One study was classified as having an unclear risk of bias for the 
“incomplete outcome data” parameter [28], as the authors did not report the reason/s 
for excluding patients data from the analysis.  
 3.4 The effect of probiotics in periodontitis  
 The clinical outcome measures that were used to evaluate the effect of probiotic 
bacteria in treating periodontal diseases, included probing pocket depth (PPD), gingival 
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recession (REC), gingival index (GI), gingival bleeding index (GBI), plaque index (PI), 
bleeding on probing (BOP) and clinical attachment (CAL), as well as quantitative and 
qualitative analysis of the burden of intra oral periodontal pathogens. 
 Of the five studies that compared the mechanical periodontal treatment alone or 
associated with probiotic administration in managing chronic periodontitis 
[16,17,22,32,33], two studies [16,22] showed higher reduction of PPD, BOP, GI and 
PI in the probiotics groups (p<0.05) during a long-term follow up period of up to 360 
days. In the study of Laleman et al. [32] only PI was significant lower (p<0.05) after 
mechanical procedures and probiotic administration compared with the control group, 
at 24-weeks. In turn, Teughels et al. [17] found a significant reduction in full-mouth 
PPD after administration of two strains of L. reuteri (DSM17938 and ATCC PTA5289), 
as well as an associated significant gain in CAL after 12 weeks of follow up, in lesions 
with moderate to deep pockets (p<0.05). The PI and BOP were both consistently lower 
in the probiotic group, although these differences were statistically significant only in 
a few occasions over the time course of the clinical trial. The single trial testing L. 
rhamnosus (SP-1) found no difference in the clinical improvement between the 
probiotic and the control groups [33]. However, in the same study, at initial visits and 
after 1-year follow up, the probiotics induced a statistically significant (p<0.05) 
reduction in number of patients with PPD ≥ 6mm, reducing the need for surgery, 
compared with the placebo group. [33] .  
  Only one of 12 selected studies evaluated the effect of probiotics in aggressive 
periodontitis [23]. Here, they also performed scaling and root planning prior to L. brevis 
and/or antibiotic administration. Their results indicated that either probiotic alone, 
probiotic plus antibiotic, and antibiotic alone were able to reduce significantly (p<0.05) 
the PPD, GI, PI and CAL after 2 months of follow up.  
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 A total of five studies [18,27,28,30,31] tested the effect of probiotics without 
prior mechanical periodontal treatment, in patients with periodontitis.   Della Riccia et 
al. [27]   detected a highly significant reduction in gingival inflammation, calculus 
levels and temperature sensitivity after treatment with L. brevis containing lozenges 
(p<0.0001). Additionally, all patients with gingival inflammation rated as 
moderate/diffuse before treatment, showed no signs of gingivitis after probiotic 
administration. For instance, bleeding on probing had an impressive reduction from 
1.38 ± 0.19 to 0.05 ± 0.05 (p<0.0001) after probiotic therapy. Similarly, Vicario et al. 
[28] also showed a significant (p<0.05) improvement of periodontal parameters (PPD, 
PI, BOP) after 30 days of treatment with two L. reuteri strains (ATCC 55730 and ATCC 
PTA5289).  
 Suzuki et al. [18] found a significant reduction of BOP, but not in PPD, after the 
application of L. salivarius WB21 containing soybean oil in comparison to the placebo 
(p=0.010). Incidentally, they noted, a significant increase in the volume of stimulated 
salivary flow after two weeks of probiotic consumption (p<0.05). On the contrary, 
Shimauchi et al. [31] were unable to show a significant improvement in periodontal 
health, in terms of clinical parameters, between the test group (L. salivarius 
WB21/xylitol) and the placebo group (xylitol alone). However, they described a 
significant improvement in PI and PPD within the cohort of current smokers in the 
probiotic group in comparison to those in the placebo group [31]. 
 As opposed to the aforementioned studies, Vivekananda et al. [29] performed a 
split mouth study, in which the effects of L. reuteri strains (DSM17938 and ATCC 
PTA5289) were tested in quadrants with or without prior scaling and root planning 
(SRP), within the same subject. They noted a maximum reduction of PPD, CAL indices 
in the group that had a combination therapy with SRP and the probiotic (p<0.001). The 
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probiotic alone also showed better results than SRP alone for three parameters, PI, GI 
and GBI.  
  A total of seven studies assessed microbiological parameters to evaluate the 
effect of probiotics on the oral burden of periodontal pathogens [16-18,23,29,30,32]. In 
one study, the proportion of obligate anaerobes was reduced after the probiotic 
treatment (p<0.005), although this difference could not be maintained after a 12-months 
follow up period [16]. In another study by Teughels et al. [17], L. reuteri administration 
was shown to promote a large and significant reduction in Porphyromonas gingivalis 
numbers in subgingival and supragingival environment, as well as in saliva over a 12-
week period [17]. In one more study using L. salivarius, the burden of Tannerella 
forsythia tended to decrease (p=0.073) after probiotic consumption [18]. The same 
group found that the number of Prevotella intermedia increased in the placebo group 
(p=0.045), but did not change in the group receiving L. salivarius. Vivekananda et al. 
[29] also noted a beneficial effect of probiotics, either alone or in combination with the 
mechanical treatment, in reducing Aggregatibacter actinomycetemcomitans, 
Porphyromonas gingivalis, and Prevotella intermedia in relatively deep pockets of 5-7 
mm (p<0.01). On the other hand, Shah et al. [23] found no significant reduction of A. 
actinomycetemcomitans counts in saliva after treatment with L. brevis.  
 The study evaluating L. salivarius in combination with xylitol in tablet 
formulations [30] assessed the effect of the probiotic at 4- and 8-weeks after two-month 
intervention period. The authors reported a significant numerical decrease in five 
selected periodontal pathogens (A. actinomycetemcomitans, P. intermedia, P. 
gingivalis, T. forsythia, and Treponema denticola) in the subgingival plaque after 
probiotic administration at the four-weeks time point (p=0.012). Individually, a 
significant reduction in T. forsythia at both time points (four- and eight-weeks) was 
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found in the subgingival plaque of the probiotic group (4-weeks p<0.001, and 8-weeks 
p=0.006).  
 Only one of the 12 selected studies, used streptococci as probiotics for managing 
periodontal disease [32]. In that study, Laleman et al [32] using three different strains 
belonging to Streptococcus oralis, S. uberis, and S. rattus species found no significant 
difference in the PPD, REC, CAL, BOP and GI after probiotic therapy. However, the 
percentage of sites with dental plaque was significantly lower (p<0.05) in the probiotic 
group than in the control group 12 weeks after the end of the treatment, and also the 
level of P. intermedia levels in the periodontal pockets was significantly reduced after 
therapy.  
3.5 Compliance and adverse effects of probiotics  
 No adverse effects of probiotic administration were reported in the RCTs 
included in this review. Positive patient compliance with probiotics administration was 




 The mainstay of the management of periodontal disease is the reduction and 
elimination of specific periodontal pathogens (periodontopathogens/pathobionts) by 
debridement which includes scaling and root planning [27]. Antimicrobial agents can 
also be used in conjunction with mechanical procedures to reduce the pathogenic 
microbial burden and provide a satisfactory clinical outcome particularly in chronic 
situations [35,36]. However, the frequent recolonization of treated sites by periodontal 
pathogens and recurrence of disease, and the emergence of antibiotic resistance in these 
pathobionts have led to calls for new approaches for the management of periodontitis, 
especially chronic periodontitis that affects millions of people worldwide.  
 One rather radical or innovative approach that has been attempted during the last 
few decades is to manage a number of infectious diseases through administration of 
probiotics, so that the disease causing pathogens are eliminated, promoting the 
development of a healthy flora, thus leading to restoration of health [20,37,38]. 
Consequently, there has been an increasing interest in the use of probiotics for oral 
infections [39], including periodontal diseases. In this systematic review, we attempted 
to collate the available clinical and microbiological evidence on the utility of probiotics 
in the management of chronic periodontitis. 
 As this is a relatively new area of study, only a handful of randomized clinical 
trials that fitted the well-defined exclusion and inclusion criteria were found. On 
analysis of the data from the twelve selected studies it is safe to conclude that three 
Lactobacillus species, i.e. L. reuteri, L. salivarius, and L. brevis that have been selected 
as probiotics improved the clinical parameters of periodontal disease in the targeted 
patient cohorts. However, the same beneficial results could not be noticed with L. 
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rhamnosus SP-1 and the Streptococcus species, demonstrating the species specificity 
of probiotics in managing periodontitis. The reduction in probing pocket depth and 
clinical attachment loss, the two most common clinical parameters of periodontitis [40], 
were significantly reduced after administration of all three Lactobacillus probiotics. 
Gingival and plaque index [41], and bleeding on probing [42] also improved due to the 
probiotic therapy in most of the studies.  
 Clearly, due to the lack of consensus on probiotic administration procedures, a 
number of protocols varying in dosage, frequency and duration have been used in the 
different studies. These include frequency of tablet, lozenge or suspension 
administration that varied from one [28] to four times [27] per day, and the intervention 
period ranging from four days [27] to 12 weeks [16,22,32]. Although not comparable, 
these variables did not seem to significantly influence the outcome, as the PI, BOP and 
gingival inflammation improved in all patient cohorts reported. Nevertheless, it is 
important in future studies to agree on a standardized protocol, such as the period, the 
dosage and the frequency of probiotic administration so as to yield broadly comparable 
data. 
 The range of Lactobacillus and Streptococcus concentrations used in the 12 
studies evaluated is noteworthy. Depending on the frequency and concentration of 
bacteria in the probiotic product, patients received suspensions ranging from 2-4 x 108 
CFU/day of L. reuteri and L. brevis, to 1.2-2.0 x 109 CFU/day of L. salivarius, 2 x 107 
CFU/day of L. rhamnosus and 6.0 x 108 CFU/day of Streptococcus spp. Concentration 
of the probiotic in the products was not specified in three studies [16,22,27]. The PPD 
of patients receiving probiotic therapy was significantly reduced (p<0.05) in two 
different studies that used L. reuteri at a concentration of 2 x 108 [28] and 4 x 108 
CFU/day [17]. On the other hand, in the most recent study where L. rhamnosus was 
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tested at a low concentration (2 x 107 CFU/day), no significant differences were noted 
between the test and control groups for PPD, CAL, PI and BOP [33]. Thus, it is difficult 
to surmise the optimal concentration of the probiotic dose and further research is 
warranted to ascertain the ideal dose profile for the improvement of clinical parameters 
of periodontitis. 
 Mechanical periodontal treatment prior to probiotic intervention was another 
variation of the protocols used in five studies [16,17,22,29,33]. The initial periodontal 
therapy included scaling and root planning with an ultrasonic scaler and hand 
instruments. The adjunct probiotic therapy after debridement led to improvement in 
clinical parameters including PPD and CAL compared with the control population, 
which did not receive probiotics, but only SRP [22,29]. Such attachment gain in 
moderate and deep pockets, and the consequent reduction of pocket depth obviates the 
necessity for surgical intervention and it is tempting to suggest that this may be a further 
benefit of the probiotic therapy [17,33].  
 Microbiological parameters were used as outcome measures in seven of the 
twelve studies. A total of six studies showed the capacity of probiotics to reduce the 
aggregate number of periodontal pathogens when probiotic therapy and mechanical 
procedures were either combined or not [16-18,29,30,32]. These observations are 
supported in in vitro investigations that demonstrated the antimicrobial activity of 
lactobacilli against A. actinomycetemcomitans, P. gingivalis, P. intermedia and 
Prevotella nigrescens [43,44].  
 The effect of probiotic therapy in combination with xylitol was investigated by 
two groups [30,31]. Xylitol, a naturally occurring a low-calorie pentose sugar 
substitute, is known for its ability to suppress growth and metabolism of cariogenic 
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mutans streptococci in particular [45]. However, a little known effect of xylitol is its 
ability to launch an anti-inflammatory response in macrophages infected with the 
periodontopathogen P gingivalis [46,47]. Shimauchi et al. [31] evaluated this 
phenomenon, and they did not find any significant improvement in clinical parameters 
of periodontitis between the control group (placebo + xylitol) and the test group 
(probiotic + xylitol). On the other hand, Mayanagi et al. [30] noted a greater reduction 
in T. forsythia in the subgingival plaque after treatment with probiotic and xylitol in 
comparison with xylitol alone, despite the claims of its antimicrobial effect.  
 The mechanisms underlying the observed salutary effect of probiotics in reducing 
the burden of periodontopathic organisms as reported by several investigators is unclear, 
as yet. As per the ecological plaque hypothesis [48], the ability of probiotics to tip the 
overall composition of the periodontal biofilm in favor of commensals and eliminate 
the dysbiosis caused by periodontopathogens (the so called `red complex bacteria`) 
could be one reason for such observations. Other possible mechanisms of probiotic 
action may include the competitive inhibition of adhesion sites, and nutrient depletion 
[49,50]; modulation of the immune system [22,51]; modulation of cell proliferation and 
apoptosis [52]; production of antimicrobial substances, such as lactic acid, hydrogen 
peroxide and reuterin [49,53]; and modulation of the pH and/or the oxidation–reduction 
potential of the plaque biofilm [9] (Figure 2). Some examples of the above could be 
gleaned from the evaluated studies. For instance, Ince et al. [22] reported a reduction  
of matrix metalloproteinase-8 (MMP-8) levels in the gingival crevicular fluid in chronic 
periodontitis after probiotic treatment. Active MMP-8 is the main host cell-derived 
collagenase that leads to periodontal tissue destruction and it is mostly found in sites 
with progressive periodontitis [54]. An increased level of tissue inhibitor of 
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metalloproteinases-1 (TIMP-1), which has inhibitory effect against all MMPs, was also 
noted in patients treated with probiotic [22]. 
 L. brevis possesses arginine-deaminase that metabolizes arginine to citrulline and 
ammonia [27]. The competition inhibition of nitric oxide synthase (NOS) by arginine-
deaminase may cause the probiotic to suppress nitric oxide generation, an important 
inflammatory mediator in periodontitis [55]. Indeed, Della Riccia et al. [27], in their 
studies noted that the probiotic treatment was associated with a significant decrease in 
the NOS activity. The variation of all these inflammation-associated markers 
strengthens the evidence of the anti-inflammatory capacity of probiotics. Also 
noteworthy is the study of Shimauchi et al. [31], which showed that probiotics 
significantly decreased the salivary lactoferrin levels in smokers with chronic 
periodontitis. Lactoferrin is a member of the transferrin family of iron-binding proteins 
and its high salivary concentration is associated with periodontal inflammation [56].  
 As regards safety, probiotics are traditionally considered to be safe for human 
consumption with negligible adverse side effects [57]. None of the RCTs reported 
adverse effects, such as stomach upset, gastrointestinal disorder, headache and 
nausea/vomiting [28]. This is a critical requirement if probiotics are proposed as an 
adjunct in the management of periodontal disease, particularly, because they need to be 
continuously administered for prolonged periods for the maintenance of a healthy 
periodontal flora. 
 To conclude, our systematic review indicates that the oral administration of 
probiotics is an effective adjunct in the management of periodontitis, reducing 
periodontopathogenic bacteria and improving the clinical signs of the disease, although 
strain specificity of the probiotic appears to be important for the observed beneficial 
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effects. Clinical improvement was achieved with three Lactobacillus species, (L. 
reuteri, L. salivarius, and L. brevis), but not by a Streptococcus strains and L. 
rhamnosus. The mechanisms underpinning the effect of probiotics in alleviating 
periodontal infection is unclear as yet, although it is highly likely that probiotics play a 
critical role in nurturing a healthy gingival flora and deterring the colonization of the 
periodontal niche by the periodontopathogens. Further studies are warranted in order to 
confirm the findings of the relatively few, appropriately controlled studies available in 
the literature, as probiotic therapy could be an attractive supplementary adjunct for 
traditional therapies in managing periodontal disease. 
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6. EXPERT COMMENTARY  
 Periodontal diseases are arguably the commonest human affliction. Of the 
periodontal diseases,   periodontitis,   a chronic inflammatory disease that compromises 
supporting structures of the tooth (gingivae, periodontal ligament and alveolar bone), 
is particularly insidious due to its slow relentless, silent and chronic progression leading 
to eventul tooth and bone loss and deteriotating the overall  quality of life of the affected 
patient. 
.  
 The aetiology of periodontitis is complex and involves polymicrobial 
interrelationships that disrupt the fine balance of the  oral  microbiome associated with 
periodontal tissue homeostasis. The development   periodontal disease is intimately 
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connected to a    shift from a symbiotic dental biofilm, composed mostly of facultative 
anaerobic bacteria (e.g. Actinomyces and Streptococci), to a dysbiotic microbial 
community of anaerobic microbes from the phyla  essentially belonging to Spirochaetes, 
Bacteroidetes, Firmicutes, Proteobacteria, and Synergistetes.  
 Periodontal pathogens, besides causing tooth loss, may adversely affect the 
systemic health of patients. Bacteremias   atherosclerotic vascular disease, adverse 
pregnancy outcomes, diabetes and nosocomial pneumonias have  all been linked to 
periodontal pathogens and their byproducts. Hence, maintaining the homeostasis of the 
oral microbiome, as well as the conversion of   a diseased, dysbiotic microbiome  to a 
symbiotic state is critically important for to maintain oral and systemic health.  
 The conventional treatment modalities of periodontitis include non-surgical 
management, which  entails   debridement of the pathogenic, dysbiotic biofilm from 
the tooth surfaces by mechanical procedures,  such as scaling, together with improved  
oral hygiene regimens, and in some cases accompanied by antibiotic therapy. However, 
the high incidence of recurrence of periodontitis caused by frequent recolonization of 
treated sites by periodontopathogens, and the adverse side effects of antibiotics, 
including the potential emergence of resistant organisms, have led to a call for new 
therapeutic approaches for managing periodontal diseases. 
 Consequently, the use of probiotic bacteria has emerged as an alternative 
therapeutic technique for infectious diseases in the oral cavity. Probiotics are live 
microorganism able to combat pathogens without being harmful to the host. To be 
considered a probiotic, the microorganism needs to be of human origin, preferably 
isolated from the human gut, and devoid of intrinsic and transmissible antibiotic 
resistance genes. The safety of probiotic bacteria has been clearly demonstrated in all 
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the clinical trials included in the present review, as no adverse effects were reported by 
the patients during probiotic therapy.   
 Bacteria belonging to the genera Lactobacillus have been traditionally used as 
probiotics for many decades. Now, they are deemed worthy as an alternative biological 
approach to combat periodontopathogens, as shown by the randomized controlled trials 
included in this systematic review.  
 Probiotic bacteria, especially lactobacilli, were effective adjunct for treating 
periodontal disease, particularly when combined with mechanical removal of 
pathogenic biofilms. Emerging data reviewed here indicate that adjunctive use of 
specific probiotic supplements leads to significant amelioration of disease indices 
(probing pocket depth, gingival index, plaque index, bleeding on probing, and clinical 
attachment level), and reduces the need for antibiotics and surgery procedures. These 
clinical improvements were closely associated with significant alterations in the 
microbial profile of the periodontal pocket,    reducing the  the burden of traditional 
periodontopathogens, such as Porphyromonas gingivalis, Tannerella forsythia, 
Prevotella intermedia, and Aggregatibacter actinomycetemcomitans. However, it was 
disappointing to note that only a few attempted to investigate the mechanisms 
underlying the action of probiotics against oral pathogens. This area is worthy of further 
exploration and may yield clues to microbial behaviour in the oral ecosystem that could 
be exploited for further therapeutic purposes in future.   
 
  
 To conclude, the data presented in   this systematic review conclusively imply   
that probiotic bacteria can be used as an adjuvant to conventional treatment of 
 22 
periodontitis with no side effects  on the host. They may  augment the antimicrobial 
effect of mechanical plaque removal , reducing the necessity  for surgical intervention, 
and replace antibiotics in the management of human periodontal infections in future. 
7. FIVE-YEAR VIEW 
The clinical efficacy of probiotic administration in the war against periodontal disease 
and its perpetrating bacterial flora will gain popularity based on underlying scientific 
evidence. The mechanisms of action of probiotics against oral pathogens will be better 
understood, nurturing further the development of commercial probiotic products and 
their use to combat oral diseases such as periodontitis.  
8. KEY ISSUES 
• Periodontitis is one of the commonest human afflictions leading to  tooth loss, 
but may also affect the systemic health by increasing the patients’ risk for 
atherosclerotic vascular disease, adverse pregnancy outcomes, diabetes and 
nosocomial pneumonias. 
• Adverse side effects of antibiotics, including the potential emergence of 
resistant organisms, limit their routine and long term use in managing the 
chronic periodontal diseases. The frequent recolonization of treated sites by 
periodontopathogens is also a clinical dilemma. 
• Of the 12 clinical trials selected (from 214) in this systematic review, through a 
rigorous filter procedure, all trials that used Lactobacillus species as probiotics 
yielded favorable clinical outcomes in terms of a reduction of the conventional 
disease indices such as probing pocket deep (PPD), bleeding on probing (BOP), 
gingival index (GI) and plaque index (PI), with probiotic administration and 
concomitant scaling and root planning (conventional mechanical treatment). 
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• One randomized controlled trial testing Steptococcus spp. as a probiotic showed 
no significant difference between the probiotic and the placebo groups 
regarding PPD, BOP, GI and clinical attachment level (CAL), although P. 
intermedia counts were reduced in the probiotic group after 12 weeks of 
treatment.  
• In some studies, significant reduction in gingival inflammation (gingivitis) was 
observed after treatment with Lactobacillus alone, without prior mechanical 
treatment. 
• Oral administration of lactobacilli significantly reduced (p<0.05) the oral 
burden of periodontal pathogens, such as Aggregatibacter 
actinomycetemcomitans, Porphyromonas gingivalis, and Prevotella intermedia. 
The maintenance of this beneficial effect was dependent on continuous 
probiotic consumption.  
• The mechanisms of action of probiotics are unclear, as yet, although it is likely 
that they play a critical role in nurturing a healthy gingival flora and deterring 
the recolonization of the periodontal niche by periodontopathogens.  
• Probiotics may serve as adjunct or replacement therapy to substitute antibiotics 
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